Keep in touch

Sub-Licensees

 

Aurobindo Pharma Limited

Sub-licences covering: tenofovir alafenamide (TAF), atazanavir (ATV), abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In September 2014, Aurobindo, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Aurobindo to manufacture the novel investigational medicines tenofovir alafenamide (TAF).

In July 2014, the MPP, Aurobindo and Bristol-Myers Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir (ABC) for paediatric use. This sublicensing agreement has been amended in November 2014 following the announcement of the extension of the MPP-ViiV Healthcare licence agreement to 121 countries.

In September 2011, the MPP signed a sublicensing agreement with key generics manufacturer Aurobindo covering FTC, COBI, EVG, and the Quad. Aurobindo chose to take advantage of a key provision negotiated by the MPP so it can sell tenofovir to a larger number of countries and without paying royalties.

top

Cipla

Sub-licences covering: atazanavir (ATV), tenefovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], dolutegravir (DTG)

In November 2014, Cipla, the MPP and Bristol-Myers Squibb signed a sublicensing agreement related to the antiretroviral medicines atazanavir (ATV).

In September 2014, Cipla, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Cipla to manufacture the novel investigational medicines tenofovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

 

Desano

Sub-licences covering: dolutegravir (DTG) tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat(COBI) and atazanavir (ATV)

In November 2014, the MPP, Desano and ViiV Healthcare signed a sub-licensing agreement allowing Desano to manufacture dolutegravir (DTG) for adults and paediatrics use.

In September 2014, the MPP, Desano and Gilead Sciences signed a sub-licensing agreement allowing Desano to produce a generic version of tenofovir alafenamide (TAF) and also of  tenofovir disoproxil fumarate (TDF), emtricitabine and cobicistat.

In May 2014, the MPP  and Bristol-Myers Squibb signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano allowing it to manufacture atazanavir (ATV).

top

Emcure Pharmaceuticals Limited

Sub-licences covering: dolutegravir (DTG), tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

In October 2014, the MPP, Emcure and ViiV Healthcare signed a sub-licensing agreement allowing Emcure to manufacture dolutegravir (DTG) for adults and paediatrics use.

In September 2014, Emcure, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Emcure to manufacture the novel investigational medicines tenofovir alafenamide (TAF). The recent agreement replace the former sub-licensing agreement dated February 2012.

In July 2014, the MPP and Bristol-Myers Squibb signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV).

In January 2012, the MPP signed a sublicensing agreement with key generics manufacturer Emcure covering FTC, COBI, EVG, and the Quad.  Emcure chose to take advantage of a key provision negotiated by the MPP so it can sell tenofovir to a larger number of countries and without paying royalties.

top

Hetero Labs

Sub-licences covering: tenofovir alafenamide (TAF), dolutegravir (DTG), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In September 2014, Hetero Labs, the MPP and Gilead Sciences signed a sub-licensing agreement allowing Hetero Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF). The recent agreement replace the former sub-licensing agreement dated July 2012.

In August 2014, Hetero Labs, the MPP and ViiV Healthcare signed a sub-licensing agreement allowing Hetero to manufacture a generic version of dolutegravir (DTG) for both paediatrics and adults use.

In July 2012, the MPP, Hetero Labs and Gilead Sciences signed a sub-licensing agreement with the key generic manufacturer Hetero Labs overing FTC, COBI, EVG, and the Quad.  Htero Labs chose to take advantage of a key provision negotiated by the MPP so it can sell tenofovir to a larger number of countries and without paying royalties.

top

Laurus Labs

Sub-licences covering: tenofovir alafenamide (TAF), dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

In September 2014, Laurus Labs, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Laurus Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF). This recent agreement replace the former sub-licensing agreement dated September 2012.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

In September 2012, the MPP signed a sub licensing agreement with key generics manufacturer Laurus covering TDF, FTC, COBI, EVG, and the Quad.

top

Micro Labs

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Micro Labs allowing it to manufacture dolutegravir for both adult and paediatric treatment.

top

Mylan

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Mylan allowing it to manufacture dolutegravir for both adult and paediatric use.

top

Shasun Pharma Solutions

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

On 25 February 2013, the MPP and Gilead Sciences signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Shasun Pharma Solutions for  tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

top

Shilpa Medicare

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In June 2013, the MPP, Shilpa Medicare and Gilead signed a sublicensing agreement allowing it to manufacture five key HIV medicines  licensed to the MPP by Gilead Sciences in July 2011.

top

This page is also available in: French, Spanish